EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)
详细信息 查看全文
- 作者：Jan Tennvall ; Manfred Fischer ; Angelika Bischof Delaloye ; Emilio Bombardieri ; Lisa Bodei ; Francesco Giammarile ; Michael Lassmann ; Wim Oyen and Boudewijn Brans
- 关键词：Guidelines ; Nuclear medicine ; 90Y ; ibritumomab tiuxetan ; Non ; Hodgkin’ ; s lymphoma ; Radioimmunotherapy
- 刊名：European Journal of Nuclear Medicine and Molecular Imaging
- 出版年：2007
- 出版时间：April, 2007
- 年：2007
- 卷：34
- 期：4
- 页码：616-622
- 全文大小：136 KB
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Nuclear Medicine
Imaging and Radiology
Orthopedics
Cardiology
Oncology - 出版者：Springer Berlin / Heidelberg
- ISSN：1619-7089
文摘
Background In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin’s lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine.